

Speaker	Session Title	Date	Location	Individual's Role(s) in Activity	Nature of relationship to ineligible company
Maureen Okam Achebe, MD, MPH	Updates on Current, Emerging and Curative Therapies for Sickle Cell Disease	January 10 - 11, 2025	New York, NY	Speaker	Consultancy: Vertex Pharmaceuticals Membership on a Board or Advisory Committee: Global Blood Therapeutics, Pharmacosmos, Shield Therapeutics, Vertex Pharmaceuticals
Susan Bal, MD	Innovations in Multiple Myeloma and Plasma Cell Dyscrasias: Charting the Path Forward	January 10 - 11, 2025	New York, NY	Speaker	Consultancy: AbbVie, AstraZeneca, Bristol Myers Squibb, Janssen, Pfizer Research Funding: AbbVie, BeiGene, Bristol Myers Squibb, Fate Therapeutics Honoraria: Adaptive Biotechnology
Paul Barr, MD	Highlights in Aggressive and Hodgkin Lymphomas	January 10 - 11, 2025	Seattle, WA	Speaker	Consultancy: AbbVie, Adaptive Therapeutics, AstraZeneca, Beigene, Bristol Myers Squibb, Genentech, Gilead, Janssen, Morphosys, Seattle Genetics, TG Therapeutics Research Funding: AbbVie, AstraZeneca, TG Therapeutics Membership on a Board or Advisory Committee: TG Therapeutics
Tyler Buckner, MD, MSc	Inherited Disorders of Coagulation	January 10 - 11, 2025	Seattle, WA	Planner/Speaker	Consultancy: BioMarin (ended 8/16/2023) Honoraria: Novo Nordisk (ended 4/1/2023), Octapharma (ended 12/9/2022), Sanofi (ended 7/11/2024)
Patrick Burke, MD	ALL Updates from ASH: First line targeted therapy in Ph- and Ph+ ALL and a new CAR-T!	January 10 - 11, 2025	Seattle, WA	Speaker	Consultancy: Servier
Cecelia Calhoun, MD, MPH, MBA	Updates on Current, Emerging and Curative Therapies for Sickle Cell Disease	January 10 - 11, 2025 January 17- 18, 2025	Seattle, WA Chicago, IL	Speaker	Consultancy: CVS Caremark, Sanius Health Membership on a Board or Advisory Committee: BlueBird Bio
Carla Casulo, MD	Highlights in Aggressive and Hodgkin Lymphomas	January 10 - 11, 2025	Seattle, WA	Speaker	Consultancy: AbbVie, BMS, Genentech, Genmab Honoraria: AbbVie, BMS, Genentech Membership on a Board or Advisory Committee: Genentech Research Funding: Genentech
Alexey Danilov, MD, PhD	The Evolving Role of Targeted and Immunotherapy in Indolent Lymphoma and Chronic Lymphocytic Leukemia	January 10 - 11, 2025	Seattle, WA	Speaker	Consultancy: AbbVie, AstraZeneca, Beigene, Bristol Meyers Squibb, Genentech, Incyte, Lilly Oncology, MEI, Merck, Morphosys, Nurix, Pharmacyclics, Regeneron Research Funding: AbbVie, AstraZeneca, Bayer, Beigene, Bristol Meyers Squibb, Cyclacel, Genentech, Lilly Oncology, MEI, Merck, Nurix, Regeneron, SecuraBio, Takeda Oncology
Courtney D. DiNardo, MD	Acute Myeloid Leukemia	January 31 - February 1, 2025	Washington, DC	Speaker	Consultancy: AbbVie, AstraZeneca, BMS, Cleave, Schrodinger, Servier Research Funding: Astex, BMS, Celgene, Cleave, Daiichi Sankyo, Foghorn, Loxo, Schrodinger, Servier Honoraria: Astellas, Celgene, Daiichi Sankyo, GSK, Loxo, Servier Membership on a Board or Advisory Committee: Abbvie, AstraZeneca, GenMab, GSK, Servier
Adam Duvall, MD	ALL Updates from ASH: First line targeted therapy in Ph- and Ph+ ALL and a new CAR-T!	January 17- 18, 2025			

Speaker	Session Title	Date	Location	Individual's Role(s) in Activity	Nature of relationship to ineligible company
---------	---------------	------	----------	-------------------------------------	--

Speaker	Session Title	Date	Location	Individual's Role(s) in Activity	Nature of relationship to ineligible company
Sarah Rutherford, MD	Highlights in Aggressive and Hodgkin Lymphomas	January 10 - 11, 2025	New York, NY	Speaker	Consultancy: ADC Therapeutics, BMS, GenMab, Karyopharm, Kite, Pfizer, Seagen Honoraria: Aptitude Health, Curio Science, Physicians' Education Resource, Plexus Communications Membership on a Board or Advisory Committee: Karyopharm Research Funding: Constellation, Genentech, Karyopharm
Bethany Samuelson Bannow, MD, MCR	A Day in the Life of a Schematologist: Exploring the Intersection of Hematology and Women's Health	January 10 - 11, 2025	Seattle, WA	Speaker	Membership on a Board or Advisory Committee: Hema Biologics
Bart L. Scott, MD	Classical Insights in Transplantation	January 10 - 11, 2025 January 31 - February 1, 2025	Seattle, WA Washington, DC	Speaker	Consultancy: Agios, Celgene, Jazz, Taiho Oncology Honoraria: Agios, Alexion, BMS, Celgene, Geron Speakers Bureau: Agios, Alexion, BMS, Celgene, Geron, Incyte, Novartis, Taiho Oncology Research Funding: Incyte, Jazz, Novartis
Joseph Shatzel, MD, MCR	Consultative Hematology: What Are My Other Options?	January 10 - 11, 2025 January 31 - February 1, 2025	Seattle, WA Washington, DC	Speaker	Nothing to disclose.
Melody Smith, MD, MS	Classical Insights in Transplantation	January 17- 18, 2025	Chicago, IL	Speaker	Consultancy: A28 Therapeutics Membership on a Board or Advisory Committee: CVS Caremark
Deborah Stephens, DO	The Evolving Role of Targeted and Immunotherapy in Indolent Lymphoma and Chronic Lymphocytic Leukemia	January 17- 18, 2025	Chicago, IL	Speaker	Consultancy: AbbVie, AstraZeneca, Beigene, BMS, Celgene, Eli Lilly, Genentech, Janssen, Pharmacyclics, TG Therapeutics Research Funding: AstraZeneca, BMS, Genetech, Novartis
Douglas Tremblay, MD	Moving the Needle in the Treatment of Myeloproliferative Neoplasms and Chronic Myeloid Leukemia	January 10 - 11, 2025	New York, NY	Speaker	Consultancy: AbbVie, Cogent Biosciences, Novartis, PharmaEssentia, Sierra Oncology, Sobi Research Funding: Cogent Biosciences, Geron, Gilead, Sobi, Sumitomo
Eric Tse, PhD, MBBS	N/A	N/A	N/A	Planner	Consultancy: Merck Sharp & Dohme Honoraria: AbbVie, Beigene, Merck Sharp & Dohme, Roche
Michelle Zeller, MD, MHPE, FRCPC, DRCPSC	Transfusion Medicine	1, 2025			